SAB Biotherapeutics, Inc. (SABS): R&D Expense
$34.35M
Year ended 2025-12-31
-1.9%
3-year compound annual growth
+4.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $34.35M | +13.6% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $30.25M | +83.2% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $16.52M | -54.7% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $36.44M | -36.3% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $57.18M | +104.9% | 2023-04-28, From 2021-01-01 |
| 2020-12-31 | $27.91M | n/a | 2023-04-28, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $34.35M | +13.6% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $166.42M | -34.0% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $109.44M | -15.9% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $90.30M | +23.2% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $142.67M | +46.8% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $29.79M | +73.1% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $89.95M | -54.9% |
| Compugen Ltd (CGEN) | 2025-12-31 | $22.76M | -8.3% |
Compare SABS, STRO, CRBU, AURA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗